Neuroreceptor imaging of schizophrenia

doi:10.1017/CBO9780511782091.005

4 - Neuroreceptor imaging of schizophrenia

from Section I - Schizophrenia

Published online by Cambridge University Press: 10 January 2011

Dean F. Wong ,

James Robert Brašić and

Nicola Cascella

Edited by

Martha E. Shenton and

Bruce I. Turetsky

Show author details

Dean F. Wong: Affiliation:
The Russel H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA
James Robert Brašić: Affiliation:
The Russell H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA
Nicola Cascella: Affiliation:
Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, MD, USA
Martha E. Shenton: Affiliation:
VA Boston Healthcare System and Brigham and Women's Hospital, Harvard Medical School
Bruce I. Turetsky: Affiliation:
University of Pennsylvania

Book contents

Get access

Summary

Introduction

Since the development of neuroreceptor positron emission tomography (PET) imaging in the 1980s, the application of this novel in-vivo technology has revolutionized the study of schizophrenia for pathophysiology and drug development. This now-coined “molecular imaging” in schizophrenia has a historical root in the very basis of in-vivo neuroreceptor imaging with PET and single-photon emission computed tomography (SPECT). Indeed, the first successful imaging study in 1983 in living human brain was with a radiolabeled antipsychotic, spiperone (Spiroperidol), labeled with [11C]-methyl iodine (Wagner et al.,1983), and later with [18F]. This was followed with the isotopic labeling of [11C]-raclopride (i.e. no change in the chemical structure or pharmacology), also an antipsychotic and D2/D3 dopamine (DA) antagonist. Both unlabeled spiperone and raclopride have been studied for their potential therapeutic value for schizophrenia in clinical trials. Although neither of these antipsychotics was used clinically, their radiolabeled PET analogs led the way for studying D2-like dopamine receptors, and opened up the entire field of studying neuroreceptors as essentially a new subspecialty of neuroimaging with tremendous application in neuropsychiatry. These two radiotracers were quickly shown to be displaceable by unlabeled marketed antipsychotics such as haloperidol (Haldol), which led ultimately to dopamine D2/D3 occupancy studies (see below), and guidance of therapeutic drug dose levels now being visualized in human brain. Most importantly, they illustrate the merging of basic psychopharmacology, CNS nuclear medicine methodology, and in-vivo neuropsychiatric applications.

Keywords

anti-psychotic medication dopamine imaging glutamate system imaging single-photon emission computed tomography serotonin imaging schizophrenia neuroreceptor imaging positron emission tomography

Type: Chapter
Information: Understanding Neuropsychiatric Disorders
Insights from Neuroimaging
, pp. 78 - 87

DOI: https://doi.org/10.1017/CBO9780511782091.005 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abi-Dargham, A, Kegeles, L S, Zea-Ponce, Y, et al. 2004. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55, 1001–06.Google Scholar

Abi-Dargham, A, Rodenhiser, J, Printz, D, et al. 2000. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97, 8104–09.Google Scholar

Adams, B W, Bradberry, C W and Moghaddam, B. 2002. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Synapse 43, 12–8.Google Scholar

Breier, A, Su, T P, Saunders, R, et al. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94, 2569–74.Google Scholar

Buchsbaum, M S, Christian, B T, Lehrer, D S, et al. 2006. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85, 232–44.Google Scholar

Carlsson, A. 1999. Birth of neuropsychopharmacology – impact on brain research. Brain Res Bull 50, 363.Google Scholar

Carlsson, A, Waters, N and and Carlsson, M L. 1999. Neurotransmitter interactions in schizophrenia – therapeutic implications. Biol Psychiatry 46, 1388–95.Google Scholar

Carson, R E, Breier, A, Bartolomeis, A, et al. 1997. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cerebr Blood Flow and Metab 17, 437–47.Google Scholar

Davidson, L L and Heinrichs, R W. 2003. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 122, 69–87.Google Scholar

Erritzoe, D, Rasmussen, H, Kristiansen, K, et al. 2006. Serotonin 2A binding in neuroleptics-naïve schizophrenic patients and healthy controls using PET and [18-F]altanserin. NeuroImage 31, T44–186 [Abstract].Google Scholar

Erritzoe, D, Rasmussen, H, Kristiansen, K T, et al. 2008. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 33, 2435–41.Google Scholar

Farde, L, Hall, H, Ehrin, E and Sedvall, G 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231, 258–61.Google Scholar

Farde, L, Wiesel, F A, Halldin, C and Sedvall, G. 1988. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45, 71–6.Google Scholar

Farde, L, Wiesel, F A, Stone-Elander, S, et al. 1990. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47, 213–9.Google Scholar

Frankle, W G, Narendran, R, Huang, Y, et al. 2005. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 57, 1510–6.Google Scholar

Grace, A A 1991. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41, 1–24.Google Scholar

Gründer, G, Carlsson, A and Wong, D F. 2003. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60, 974–7.Google Scholar

Gründer, G, Fellows, C, Janouschek, H, et al. 2008. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am J Psychiatry 165, 988–95.Google Scholar

Hurlemann, R, Boy, C, Meyer, P T, et al. 2005. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol (Berl) 210, 519–23.Google Scholar

Innis, R B, Cunningham, V J, Delforge, J, et al. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27, 1533–9.Google Scholar

Joyce, J N, Shane, A, Lexow, N, Winokur, A, Casanova, M F and Kleinman, J E 1993. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8, 315–36.Google Scholar

Krystal, J H, Abi-Saab, W, Perry, E, et al. 2005. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179, 303–9.Google Scholar

Laruelle, M. 1998. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42, 211–21.Google Scholar

Laruelle, M, Abi-Dargham, A, Casanova, M F, Toti, R, Weinberger, D R and Kleinman, J E. 1993. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry 50, 810–8.Google Scholar

Laruelle, M, Abi-Dargham, A, Dyck, C H, Gil, R and D'Souza, C D. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93, 9235–40.Google Scholar

Laruelle, M, Abi-Dargham, A, Dyck, C, et al. 2000. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 47, 371–9.Google Scholar

Martinez, D, Gelernter, J, Abi-Dargham, A, et al. 2001. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24, 553–60.Google Scholar

Matusch, A, Hurlemann, R, Rota Kops, E, et al. 2007. Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans. J Neural Transm 114, 1433–42.Google Scholar

Mukherjee, J, Christian, B T, Dunigan, K A, et al. 2002. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies and preliminary assessment of sensitivity to aging effects on dopamine D2/D3 receptors. Synapse, 46, 170–88.Google Scholar

Mukherjee, J, Christian, B T, Narayanan, T K, Shi, B and Collins, D 2005. Measurement of d-amphetamine-induced effects on the binding of dopamine D2/D3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non human primates using PET. Brain Res 1032, 77–84.Google Scholar

Mukherjee, J, Christain, B T, Narayanan, T K, Shi, B and Mantil, J. 2001. Evaluation of dopamine D2 receptor occupancy by clozapine, risperidone and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology, 25, 476–88.Google Scholar

Mukherjee, J, Shi, B, Christian, B T, Chattopadhyay, S, and Narayanan, T K. 2004. 11C-fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain. Bioorg Med Chem 12, 95–102.Google Scholar

Munro, C A, McCaul, M E, Oswald, L M, et al. 2006a. Striatal dopamine release and family history of alcoholism. Alcohol Clin Exp Res 30, 1143–51.Google Scholar

Munro, C A, McCaul, M E, Wong, D F, et al. 2006b. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry 59, 966–74.Google Scholar

Nozaki, S, Kato, M, Takano, H, et al. 2009. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 108, 78–84.Google Scholar

Nyberg, S, Olsson, H, Nilsson, U, Maehlum, E, Halldin, C and and Farde, L 2002. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 162, 37–41.Google Scholar

Oswald, L M, Wong, D F, McCaul, M, et al. 2005. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 30, 821–32.Google Scholar

Rasmussen, H, Erritzoe, D, Andersen, R, et al. 2010. Decreased frontal serotonin 2A receptor binding in antipsychotic-naïve patients with first-episode schizophrenia. Arch Gen Psychiatry 67, 9–16.Google Scholar

Reith, J, Benkelfat, C, Sherwin, A, et al. 1994. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 91, 11 651–4.Google Scholar

Singer, H S, Szymanski, S, Guiliano, J, et al. 2002. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159, 1329–36.Google Scholar

Talvik-Lotfi, M, Nyberg, S, Nordström, A L, et al. 2000. High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology (Berl) 148, 400–03.Google Scholar

Wagner, H N, Jr, Burns, H D, Dannals, R F, et al. 1983. Imaging dopamine receptors in the human brain by positron tomography. Science 221, 1264–6.Google Scholar

Wong, D F. 2002a. In vivo imaging of D2 dopamine receptors in schizophrenia: the ups and downs of neuroimaging research. Arch Gen Psychiatry 59, 31–4.Google Scholar

Wong, D F. 2002b. [Erratum] In vivo imaging of D2 dopamine receptors in schizophrenia: the ups and downs of neuroimaging research. Arch Gen Psychiatry 59, 440.Google Scholar

Wong, D F, Potter, W Z and Brašić, J R 2002. Proof of concept: functional models for drug development in humans. In Davis, K L, Charney, D, Coyle, J T and Nemeroff, C (Eds) Neuropsychopharmacology: The Fifth Generation of Progress. Baltimore, MD: Lippincott Williams and Wilkins, pp. 457–73.

Wong, D F and Brašić, J R 2005. Progress in the neuropsychiatry of schizophrenia. Psychiatric Times 22(3), 57–60.Google Scholar

Wong, D F, Gjedde, A, Wagner, H N, et al. 1986. Quantification of neuroreceptors in the living human brain. II. inhibition studies of receptor density and affinity. J Cerebr Blood Flow Metab 6, 147–53.Google Scholar

Wong, D F, Kuwabara, H, Schretlen, D J, et al. 2006. Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology 31, 2716–27. Erratum in: Neuropsychopharmacology 2007; 32, 256.Google Scholar

Wong, D F, Brašić, J R, Singer, H S, et al. 2008. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette Syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 33, 1239–51.Google Scholar

Wong, D F, Maini, A, Rousset, O G and Brašić, J R 2003. Positron emission tomography: a tool for identifying the effects of alcohol dependence on the brain. Alcohol Res Health 27, 161–73.Google Scholar

Wong, D F, Tauscher, J and Gründer, G 2009. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology, 34, 187–203.Google Scholar

Wong, D F, Wagner, H N Jr, Dannals, R F, et al. 1984. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226, 1393–6. Google Scholar

Yasuno, F, Suhara, T, Okubo, Y, et al. 2004. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161, 1016–22. Google Scholar

Yokoi, F, Gründer, G, Biziere, K, et al. 2002. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27, 248–59.Google Scholar

Zanardi, R, Artigas, F, Moresco, R, et al. 2001. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. J Clin Psychopharmacol 21, 53–8.Google Scholar

Book contents

4 - Neuroreceptor imaging of schizophrenia

Summary

Keywords

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive